INTRODUCTION {#sec1-1}
============

Radix Saposhnikoviae (Fangfeng in Chinese), the dried root of perennial herb *Saposhnikovia divaricate* (Turxz.) schischk under *Umbelliferae*, is a common traditional herbal medicine for the treatment of pyrexia, rheumatism, headache, vertigo, generalized aching, convulsion, and arthralgia and inflammatory symptoms in traditional clinical practice in Asian countries such as China, Japan, and Korea for thousands of years.\[[@ref1][@ref2][@ref3][@ref4][@ref5]\] It is noteworthy that these pharmacological activities of Radix Saposhnikoviae have also been confirmed by modern scientific experiments using its extracts.\[[@ref1][@ref5][@ref6]\] Phytochemical studies on this herb revealed the existence of abundant compounds in Radix Saposhnikoviae, such as chromones, coumarins, polyacetylenes, and polysaccharides, among which chromones and coumarins are the main components of Radix Saposhnikoviae.\[[@ref4][@ref7][@ref8]\] Of these chemicals, chromones have been identified as the main bioactive constituents most relevant to its pharmacological efficacy, such as analgesic, antifebric, anti-inflammatory, and immune-regulatory activites.\[[@ref1][@ref5]\]

Prime-O-glucosylcimifugin (PGCN) and 4'-O-β-D-glucosyl-5-O-methylvisamminol (GML) are the two major types of chromones in Radix Saposhnikoviae with clear chemical structure \[[Figure 1](#F2){ref-type="fig"}\] and thus both of them were selected as marker compounds to assess Radix Saposhnikoviae quality in Chinese pharmacopoeia, whereas the latter is used as an identification marker in Japanese Pharmacopoeia.\[[@ref3][@ref9][@ref10]\] It has been documented that PGCN exhibited significant antipyretic, analgesic, and anti-inflammatory bioactivities.\[[@ref4]\] Cimifugin, the aglycone of PGCN, is another primary component in Radix Saposhnikoviae. A previous study showed that the cimifugin in rat plasma was much higher than that of PGCN after oral administration of Radix Saposhnikoviae extract, although the latter has much higher content than the former. As thus, it was speculated that the cimifugin might represent the potential pharmacodynamic component of Radix Saposhnikoviae, and other chromone derivatives such as PGCN and GML act as prodrugs and would be absorbed into blood in forms of cimifugin\[[@ref4][@ref11]\] through biotransformation in the intestine or stomach. Indeed, this hypothesis was confirmed by a recent study, in which cimifugin and 5-O-methyvisammiol (MVL) were obtained from the incubation system composed of PGCN and intestine flora.\[[@ref10]\] In spite of that, neither pharmacodynamic or pharmacokinetic information is available with regard to GML, the another marker compound for quality control of Radix Saposhnikoviae.\[[@ref9]\] Therefore, the aims of thisstudy were to investigate the pharmacodynamic effects of GML, mainly in terms of antipyretic, analgesic, and anti-inflammatory activities, as well as its pharmacokinetics. Cimifugin and PGCN were used in this investigation for comparison.

![Chemical structures of prime-O-glucosylcimifugin (PGCN), cimifugin, and 4'-O-β-D-glucosyl-5-O-methylvisamminol (GML).](PM-13-168-g002){#F2}

MATERIALS AND METHODS {#sec1-2}
=====================

Animals {#sec2-1}
-------

Healthy adult Sprague-Dawley rats (180--220 g) and Kunming mice (20--25 g) were used for the study. Animals were kept at standard conditions of temperature (25 ± 1ºC) and 12-h/12-h light/dark cycle and relative humidity of (70 ± 10%) throughout the experimental period. The rats and mice were given free access to standard laboratory pellets and water. All experimental procedures involving animals were conducted in accordance with the guidelines of the National Institutes of Health guidelines. The experimental protocols were also reviewed and approved by the Ethical Committee of Heilongjiang University of Chinese Medicine (approval number:HUCM2014-00348). All efforts were made to minimize animal suffering and to reduce the number of animals used. The health status of animals was monitored throughout the experiment protocols, and no obvious adverse health effects were observed following administration of cimifugin, PGCN, or GML.

Reagents and treatment {#sec2-2}
----------------------

Cimifugin, PGCN, and GML (all purity ≥98%) were purchased from Shanghai Jinsui Bio-Technology Co., Ltd. (Shanghai, China). Cimifugin, PGCN, and GML were dissolved in saline for administration to animals. 2,4-Dinitrophenol (DNP) was provided by Chengdu Xiya Chemical Co. Ltd. (Chengdu, China). Xylene and pepsin were provided by Sigma-Aldrich (St. Louis, MO, USA). HPLC-grade methanol was obtained from Tianjin Guangfu Fine Chemical Research Institute (Tianjin, China). All other reagents were analytical purity. Distilled water was prepared from demineralized water and used throughout the experiment.

Evaluation of antipyretic effect of cimifugin, PGCN, and GML {#sec2-3}
------------------------------------------------------------

The antipyretic activity of the three chromone derivatives cimifugin, PGCN, and GML was evaluated using Sprague--Dawley male rats (180--220 g). The body temperature of each rat was determined using digital thermometer. Pyrexia was induced by subcutaneous injection of single dose of 30 mg/kg body weight (b.w.) DNP. To determine and compare the antipyretic activities of cimifugin, PGCN, and GML, the treatment groups were given 1, 2, and 4 mg/kg b.w. p.o. doses of these three agents, respectively. The rats in control group were administered with equivalent amounts of saline orally. The rectal temperature of each group was recorded before and 30, 60, 90, 120, and 180 min following drug administration.

Evaluation of analgesic effect of cimifugin, PGCN, and GML {#sec2-4}
----------------------------------------------------------

Hot plate test was performed to evaluate the analgesic effect of the drugs. Kunming female mice of 20--25 g were used. Experimental animals were subjected to pretesting on a hot plate set at 55 ± 0.5ºC. Animals having latency time (time for which rat remains on the hot plate surface without licking or flicking of paws or jumping off) 5--30 s were included in this study. These mice were randomly divided into different groups, receiving increasing oral doses (1, 2, and 4 mg/kg b.w.) of cimifugin, PGCN, and GML, respectively. The mice in control group were administered with equivalent amounts of saline orally. The latency time of each group was recorded before and 15, 30, 60, 90, and 120 min following drug administration. The maximal latency (cut-off) time was set at 30 s to prevent tissue damage.

Evaluation of anti-inflammatory effect of cimifugin, PGCN, and GML {#sec2-5}
------------------------------------------------------------------

To evaluate the anti-inflammatory effects of these three agents, mouse ear edema model was established as described previously.\[[@ref12][@ref13]\] Briefly, Kunming male mice of 20--25 g were used. These mice were randomly divided into different groups, receiving oral doses (1, 2, and 4 mg/kg b.w.) of cimifugin, PGCN, and GML. The mice in control group were administered with equivalent amounts of saline orally. After 30 min, the inner and outer sides of the right ear (auricle) were treated topically with xylene (0.02 mL/mouse) for 1 h, with left ear untreated as a control. Subsequently, the mice were euthanized by cervical dislocation. Punch biopsy samples of 8-mm diameter were obtained from the same parts of the left and right ears. The ear edema index was reflected by weight difference between right and left ears of each animal.

Pharmacokinetic measurement of cimifugin, PGCN, and GML {#sec2-6}
-------------------------------------------------------

Forty male Sprague--Dawley rats in each group were used in this experiment. They were randomly divided into four groups, each consisting of 10 rats. The rats in these four groups were orally administered with 6 mg/kg cimifugin, 2 mg/kg cimifugin, 6 mg/kg PGCN, and 6 mg/kg GML, respectively. 0.5, 1, 1.5, 2, 3, 5, 8, and 12 h after the drug delivery, rats were anesthetized by ether inhalation and 0.5 mLblood samples from rats were collected in heparinized tube via the orbit vein. Meanwhile, the blank plasma was obtained from saline orally administered Sprague--Dawley rats. All these plasma was centrifuged immediately at 3000 rpm for 10 min to yield plasma. Seventy percentperchloric acid 20 μLwas added to 100 μLof plasma samples. The mixture was vortexed and centrifuged at 3000 rpm for 10 min. The supernatant were subjected to 0.45 μm microporous membrane with the filtrate collected and used for subsequent HPLC analysis. Chromatographic separation and analysis were performed using an L-2000 Elite HPLC system. The analytes were subjected to a Kromasil C~18~ column (200 mm 4.6 mm i.d., particle size 5 μm), equipped with a Shim-pack security guard column. The mobile phase was a methanol (A)--water mixture with a linear gradient elution at a flow rate of 1.0 mL/min at 25ºC. The elution program was as follows:40--45% A (0--5 min); 45--60% A (5--10 min); 60--80% A (10--15 min);80--95% A (15--20 min); 95--40% A (20--30 min). The injection volume was 20μL and detection wave length was set at 254 nm.

Metabolism studies of PGCN and GML in SGF and SIF {#sec2-7}
-------------------------------------------------

Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared according to Chinese Pharmacopeia (2010).\[[@ref9]\] Briefly, SGF was prepared by dissolving and mixing 16.4 mL diluted HCl (36% HCl 234 mL diluted with water to 1 L) and purified pepsin (10 g) and diluting with water to 1 L. This test solution had a pH of 1.2. For SIF preparation, 6.8 g potassium dihydrogen phosphate was dissolved in 500 mL water. After adjusted to pH 6.8 with 0.4% NaOH, this solution was mixed with pre-made pancreatin solution and finally diluted with water to 1 L.

One hundred microgram of PGCN or GML was added to 4 mL of either SGF or SIF to yield four reaction systems, that is, PGCN/SGF (213.47 nmol/L), PGCN/SIF (213.47 nmol/L), GML/SGF (220.99 nmol/L), GML/SIF (220.99 nmol/L), respectively. These four systems were then incubated at 37ºC for 2 h and quenched with 100ºC boiling for 10 min. After evaporation to dryness, the resulting residue was reconstituted in 1 mL methanol. The precipitate was removed by centrifugation at 3000 rpm for 10 min. The supernatant was used for HPLC analysis of content of PGCN, GML, and their metabolites as described before.

*In vitro* stability studies of 5-o-methyvisammiol in rat hepatic system and blood {#sec2-8}
----------------------------------------------------------------------------------

To evaluate drug metabolic stability *in vitro* hepatic system, liver tissue was removed from rats euthanized by cervical dislocation and then mixed with normal saline by grinding in an ice bath to finally produce a 30% liver tissue homogenate. MVL or cimifugin was incubated with the homogenate at 37ºC in a shaking water bath. The metabolic stability of this chemical was evaluated following 15 min incubation.

For *in vitro* stability study in blood, blood samples from rats were collected in heparinized tube via the orbit vein and centrifuged immediately at 3000 rpm for 10 min to yield plasma. MVL or cimifuginwas then added and the mixture was incubated at 37ºC in a shaking water bath. After 15 min, the metabolic stability of this chemical was evaluated.

RESULTS {#sec1-3}
=======

Antipyretic effects of cimifugin, PGCN, and GML {#sec2-9}
-----------------------------------------------

The cimifugin, PGCN, and GML in Radix Saposhnikoviae varied a lot in antipyretic activity. Single dose injection of 30 mg/kg b.w. DNP induced a remarkable rise of rectal temperature in a time-dependent fashion. As shown in [Table 1](#T1){ref-type="table"}, cimifugin p.o. significantly and dose dependently (1, 2, and 4 mg/kg) attenuated hyperthermia in rats. The antipyretic effects at any dose started at 0.5 h after injection of DNP and remained significant at least up to 3 h. When compared with cimifugin, antipyretic activity of PGCN appeared relatively weaker; 4 mg/kg PGCN revealed less pronounced antipyretic activity than 1 mg/kg dose of cimifugin. In addition, its onset of antipyretic response was delayed, with reversal of hyperthermia starting at 2 h after administration of PGCN 1 and 4 mg/kg. As for GML, no significant pyretic effect was found (*P*\> 0.05).

###### 

Effect of Cimifugin, PGCN, and GML on 2,4-dinitrophenol-induced pyrexia

![](PM-13-168-g003)

Analgesic effects of cimifugin, PGCN, and GML {#sec2-10}
---------------------------------------------

Results showed that cimifugin p.o. exhibited a dose-dependent increase in latency time, starting at 0.5 h and lasting at least 2 h, indicating the significant analgesic activity of cimifugin. However, results from PGCN were much weaker, as the analgesic effect of this agent at 4 mg/kg was only equivalent to that of cimifugin at 1 mg/kg. GML hardly had any analgesic activity \[[Table 2](#T2){ref-type="table"}\].

###### 

Analgesic effect of cimifugin, PGCN, and GML in hot plate test

![](PM-13-168-g004)

Anti-inflammatory effects of cimifugin, PGCN, and GML {#sec2-11}
-----------------------------------------------------

In the xylene-induced ear edema, cimifugin induced a dose-dependent reduction in edema. Although PGCN also exhibited significant anti-inflammatory effects, its activity was less pronounced than cimifugin; the anti-inflammatory action of this agent at 4 mg/kg was only equivalent to that of cimifugin at 1 mg/kg. GML hardly had any analgesic activity, although an anti-inflammatory tendency was found \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of cimifugin, PGCN, and GML on xylene-induced ear edema in mice

![](PM-13-168-g005)

Pharmacokinetic study of cimifugin in rat plasma {#sec2-12}
------------------------------------------------

At first, the metabolite profiles of the three agents in plasma were qualitatively investigated. After oral administration of cimifugin, PGCN, or GML at a single dose of 6 mg/kg, rat blood sample were collected and pretreated by protein precipitation. Then these samples were separated on a Kromasil HPLC C~18~ column. Only cimifugin was identified, whereas not any constituent was detected in the plasma of GML-treated rats in the whole process of the experiment \[[Figure 2](#F3){ref-type="fig"}\]. Based on the qualitative results, cimifugin concentrations in rat plasma were further quantitatively measured before and 0.5, 1, 1.5, 2, 3, 5, 8, and 12 h after oral administration of cimifugin (2 and 6 mg/kg), PGCN (6 mg/kg), or GML (6 mg/kg). The concentration--time curve and pharmacokinetic parameters were presented in [Figure 3](#F4){ref-type="fig"} and [Table 4](#T4){ref-type="table"}, respectively. These results demonstrated that when orally administered single same dose of the three agents (all at 6 mg/kg), cimifugin was associated with a significant higher systemic exposure (*C*~max~ and AUC) than PGCN and GML. In actual fact, both *C*~max~ and AUC were 0 in the plasma of GML administered rats, which was consistent with the qualitative results as shown in [Figure 2h](#F3){ref-type="fig"} (1)-h(3).

![HPLC chromatogram for qualitative analysis of the metabolite profiles in the plasma of rats treated with cimifugin, Prime-O-glucosylcimifugin (PGCN), and 4'-O-β-D-glucosyl-5-O-methylvisamminol (GML). (a)Blank plasma samples. (b--d), blank plasma added with reference standards of cimifugin, PGCN, andGML, respectively. (e)Blank plasma added mixtures of the reference standards of three chromes derivatives. (f(1)--f(3))Plasma samples from a rat 0.5, 1, and 5 h after oral administration of cimifugin, respectively. (g(1)--g(3)), plasma samples from a rat 0.5, 1, and 5 h after oral administration of PGCN, respectively.(h(1)--h(3)) Plasma samples from a rat 0.5, 1, and 5 h after oral administration of GML, respectively.](PM-13-168-g006){#F3}

![The concentration--time curve of cimifugin in rat plasma after oral administration of cimifugin, prime-O-glucosylcimifugin (PGCN), or 4'-O-β-D-glucosyl-5-O-methylvisamminol (GML). The rats were orally administered with cimifugin (2 or 6 mg/kg), PGCN (6 mg/kg), and GML (6 mg/kg), respectively. Blood samples from rats were then collected 0.5, 1, 1.5, 2, 3, 5, 8, and 12 h following the drug delivery for HPLC analysis.](PM-13-168-g007){#F4}

###### 

Pharmacokinetic parameters of cimifugin in rat after p.o. administration of cimifugin, PGCN, and GML

![](PM-13-168-g008)

Metabolism studies of PGCN and GML in SGF and SIF {#sec2-13}
-------------------------------------------------

As only cimifugin was detected in the plasma of either cimifugin- or PGCN-treated rats and no constituents were found in GML-treated animals, we speculated that these drugs may be metabolized in the gut or directly excreted in the feces. However, the latter seems not be the case, as no traces of chromes were found in the rat stools throughout the experiment (data not shown). Thus, we investigated the metabolism of PGCN and GML in simulated gastrointestinal environment. As shown in [Table 5](#T5){ref-type="table"}, the vast majority (99.64%) of PGCN was transformed into cimifugin in SIF and a small proportion (1.99%) of transformation in SGF. As for GML, cimifugin metabolite was found neither in SGF nor in SIF. HPLC analysis showed that \~33.37% of GML degraded into a new compound, except for a small quantity of the drugs transformed into PGCN in SGF (3.09%) and SIF (0.38%). By HPLC-MS analysis, this new compound is confirmed to be the deglucosed derivative of GML, that is, MVL \[[Figure 4](#F5){ref-type="fig"}\]. Stability studies in [Figure 5](#F6){ref-type="fig"} found that \<20% cimifugin was degraded in the liver tissue homogenate and hardly any transformation occurred in plasma. In contrast, up to 44.9 and 36.0% MVL rapidly disappeared within a short span of 15 min co-incubation with *in vitro* hepatic system and plasma, respectively, suggestive of bio-inspired instability properties of this metabolite.

###### 

Metabolic study of PGCN and GML in SGF and SIF

![](PM-13-168-g009)

![Mass spectrum analysis of the new metabolite of 4'-O-β-D-glucosyl-5-O-methylvisamminol (GML) in simulated intestinal fluid (SIF). The related substance was identified as 5-O-methyvisammiol (MVL)](PM-13-168-g010){#F5}

![In vitro stability studies of 5-O-methyvisammiol (MVL) in rat hepatic system and plasma. One hundred microliters of simulated intestinal fluid (SIF) containing MVL or cimifuginwas first coincubated with 30% *in vitro* liver tissue homogenate or plasma sample of rats at 37ºC in a shaking water bath. Fifteenminutes later, metabolic stability of these two chemicals was evaluated and compared by HPLCanalysis of parent drugs left usingrelative peak area, which was obtained by designating the actual peak area at 0 min as a value of 100%.](PM-13-168-g011){#F6}

DISCUSSION {#sec1-4}
----------

To the best of our knowledge, this study is the first report on antipyretic, analgesic, and anti-inflammatory activities and pharmacokinetics of GML. The present investigation showed that this compound was not absorbed into blood and does not possess antipyretic, analgesic, and anti-inflammatory effects when orally administered, although it has long been used for quality control for Radix Saposhnikoviae in many editions of Chinese Pharmacopoeia.

Regarding the pharmacodynamic effects of the three chromone derivatives in Radix Saposhnikoviae, only PGCN, as far as we know, was documented to possess antipyretic, analgesic, anti-inflammatory, anti-platelet aggregation, and other actions.\[[@ref10][@ref14][@ref15]\] However, both previous and our present study showed that it was the aglycone, cimifugin, rather than the parent drug (PGCN) that represented the potential pharmacodynamic component.\[[@ref4]\] This is compatible with a previous study which suggested that PGCN was of a moderately absorbed compound.\[[@ref16]\] It is worthwhile to note that in this study only cimifugin, but not any trace of PGCN, was found in the plasma samples of PGCN orally administered rats, which is inconsistent with previous reports, which also found a certain amount of parent drug, although its content in blood is much lower than that of cimifugin.\[[@ref5]\] We speculated that the discrepancy might be primarily due to the dose used for study. Indeed, Our used dose of PGCN was 2--6 mg/kg, which was much lower than those used in other studies (2--6 vs. 10 mg/kg).\[[@ref5]\] In spite of that, the dose in our study might represent the real *in vivo* process of PGCN, becausethe dose of 2--6 mg/kg rat b.w. was designated based on the actual usage dosage and human--rat dose conversion.

As aforementioned, because except for cimifugin, no other components were found in the blood, the pharmacological effects of orally administered PGCN might totally arise from its dyglucosated metabolite cimifugin. Indeed, we herein found that cimifugin monomer solution took comparatively stronger antipyretic, analgesic, and anti-inflammatory effects, and PGCN have comparatively weaker pharmacological activities when it is orally administered. But when it comes to GML, no antipyretic, analgesic, and anti-inflammatory activities were found with this compound when it was orally used. Moreover, we reckon that GML might not produce any pharmacodynamic effects when orally administered, becausenot any form of this compound was traced in the blood for this delivery route.

It is rather curious that GML was not traced either in the blood or in the feces. As thus, we detected its biotransformation products in gastrointestinal using SGF and SIF. As a result, an extremely unstable metabolite MVL was obtained in the SIF. We thus hypothesizedthat GML might first was metabolized to unstable MVL, which then was absorbed into the blood and rapidly degraded by the enzymes in the blood and liver; the degradation process was perhaps exceedingly fast, and thereby we failed to detect MVL in the plasma samples. This hypothesis warrants further confirmation.

CONCLUSION {#sec1-5}
==========

To conclude, no antipyretic, analgesic, and anti-inflammatory action was observed with GML. Meanwhile, this compound is hard to be absorbed into bloodstream. Given that Radix Saposhnikoviae extract is generally administered orally, we speculate that this compound might be a nonpharmacologically active agent in real usage. Thus, it might be unscientific to evaluate the quality of Radix Saposhnikoviae based on the content of GML.
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